ECSP16062174A - Análogos de cortistatina y síntesis y usos de los mismos - Google Patents

Análogos de cortistatina y síntesis y usos de los mismos

Info

Publication number
ECSP16062174A
ECSP16062174A ECIEPI201662174A ECPI201662174A ECSP16062174A EC SP16062174 A ECSP16062174 A EC SP16062174A EC IEPI201662174 A ECIEPI201662174 A EC IEPI201662174A EC PI201662174 A ECPI201662174 A EC PI201662174A EC SP16062174 A ECSP16062174 A EC SP16062174A
Authority
EC
Ecuador
Prior art keywords
formula
found
compound
cortistatin
potent
Prior art date
Application number
ECIEPI201662174A
Other languages
English (en)
Inventor
Ramharter Juergen
D Shair Matthew
Young Ahn Jae
Efrem Pelish Henry
Bor-Jen Liau Brian
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of ECSP16062174A publication Critical patent/ECSP16062174A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

[0001] Se proporcionan en la presente nuevos análogos de cortistatina de la fórmula (A), (B) y (C), y sales farmacéuticamente aceptables, sales de amina cuaternaria, y N-óxidos de los mismos, sintetizados, en parte, por aminación reductiva de una cetona de la Fórmula (B) para proporcionar el producto aminado de la fórmula (A), como se representa en el Esquema 1, opcionalmente a través de un intermedio de imina de la fórmula (C). [0002] Además, se proporcionan nuevos análogos de cortistatina preparados por reducción de la cetona de la fórmula (B) para proporcionar un compuesto C3-hidroxilo de la Fórmula (D). Además se proporciona un compuesto de la fórmula (E), preparado por sustitución del compuesto de la Fórmula (D). Tales compuestos también se pueden convertir en un compuesto de la Fórmula (A) por tratamiento con una amina en condiciones adecuadas. [0003] Se ha encontrado sorprendentemente que los isómeros beta de la Fórmula (A), que se conoce como la Fórmula (A-1), se han encontrado como equipotentes, o más potentes, que la cortistatina A en la inhibición de la actividad de la quinasa CDK8 y la proliferación de las células AML, y también se ha encontrado que los isómeros alfa correspondientes de la fórmula (A), que se refiere como la Fórmula (A-2), también son muy potentes. Además, se ha descubierto que los compuestos de la Fórmula (B) se han encontrado activos contra el crecimiento de líneas celulares AML en cultivo y actividad de la quinasa CDK8 en las c
ECIEPI201662174A 2013-12-24 2016-07-20 Análogos de cortistatina y síntesis y usos de los mismos ECSP16062174A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920674P 2013-12-24 2013-12-24
US201461935240P 2014-02-03 2014-02-03
US201461993329P 2014-05-15 2014-05-15

Publications (1)

Publication Number Publication Date
ECSP16062174A true ECSP16062174A (es) 2018-12-31

Family

ID=52350382

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201662174A ECSP16062174A (es) 2013-12-24 2016-07-20 Análogos de cortistatina y síntesis y usos de los mismos

Country Status (30)

Country Link
US (3) US9994582B2 (es)
EP (2) EP3087080B1 (es)
JP (2) JP6494631B2 (es)
KR (1) KR20160101162A (es)
CN (2) CN110183461A (es)
AP (1) AP2016009324A0 (es)
AU (2) AU2014369834B2 (es)
BR (1) BR112016014760A2 (es)
CA (1) CA2934819A1 (es)
CL (1) CL2016001631A1 (es)
CR (1) CR20160291A (es)
DO (1) DOP2016000158A (es)
EA (2) EA201891279A1 (es)
EC (1) ECSP16062174A (es)
ES (1) ES2709480T3 (es)
GT (1) GT201600135A (es)
IL (1) IL246390A0 (es)
MD (1) MD20160089A2 (es)
MX (1) MX361652B (es)
MY (1) MY180383A (es)
NI (1) NI201600089A (es)
PE (1) PE20161405A1 (es)
PH (1) PH12016501258A1 (es)
RU (1) RU2016126503A (es)
SA (1) SA516371410B1 (es)
SG (2) SG11201605178WA (es)
SV (1) SV2016005234A (es)
TN (1) TN2016000240A1 (es)
WO (1) WO2015100420A1 (es)
ZA (1) ZA201603894B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161405A1 (es) 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN107847763A (zh) * 2015-05-08 2018-03-27 哈佛学院院长等 靶向选择适合于用皮质抑素衍生物治疗的患者
WO2016182932A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
EP3394038A4 (en) * 2015-12-23 2019-08-21 President and Fellows of Harvard College TARGETED PATIENT SELECTION FOR TREATMENT WITH SPECIFIC CORTISTANTIDE DERIVATIVES
KR20180095051A (ko) * 2015-12-23 2018-08-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유사체 및 그의 용도
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
EP3416970A4 (en) * 2016-02-19 2019-07-24 President and Fellows of Harvard College ANALOGUES OF CORTISTATIN
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
CN114921468A (zh) 2017-01-30 2022-08-19 国立大学法人京都大学 新型化合物以及调节性t细胞的制造方法
CN107028956A (zh) * 2017-03-06 2017-08-11 刘杰 一种治疗经期抑郁症的药物组合物
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
AU2018307919B2 (en) 2017-07-24 2022-12-01 Vitae Pharmaceuticals, Llc Inhibitors of RORϒ
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
EP3917523A4 (en) * 2019-02-01 2022-10-19 University of South Carolina BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USE THERE FOR CANCER THERAPY
AR127141A1 (es) 2021-09-27 2023-12-20 Univ Kyoto Método para producir células t
CA3239019A1 (en) 2021-11-24 2023-06-01 Regcell Co., Ltd. Human inducibility controllable t-cell and method for preparing same
TW202334397A (zh) 2021-11-24 2023-09-01 日商雷格細胞股份有限公司 用於治療或預防t細胞相關疾病之醫藥組合物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886589A (en) 1957-08-05 1959-05-12 Merck & Co Inc 8-methyl-5-oxyphenyl hexahydroindan compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5185152A (en) 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL105050A0 (en) 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5554187A (en) 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6074872A (en) 1996-05-15 2000-06-13 The Scripps Research Institute Cortistatin: nucleic acids that encode these neuropeptides
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
AU5902398A (en) 1996-12-31 1998-07-31 Human Genome Sciences, Inc. Cortistatin polypeptides
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
CA2372493A1 (en) 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
EP1235851B1 (en) 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
WO2001030802A2 (en) 1999-10-25 2001-05-03 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
CN1827621A (zh) * 2000-03-31 2006-09-06 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
ITMI20011445A1 (it) 2001-07-06 2003-01-06 Europ Geie Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
US20030236439A1 (en) 2002-01-30 2003-12-25 Gregory Agoston Non-steroidal analogs of 2-methoxyestradiol
DE60327946D1 (de) 2002-12-24 2009-07-23 Univ British Columbia Angiogen-wirkende trisulfat steroide und deren verwendung
MXPA05010339A (es) 2003-03-24 2005-12-14 Sterix Ltd Derivados de estrogeno como inhibidores de la esteroide sulfatasa.
JP2006526025A (ja) 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
AU2004259014B2 (en) * 2003-07-24 2009-12-17 Merck Sharp & Dohme Corp. Antibiotic compound
US20070004689A1 (en) 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
GB0421106D0 (en) 2004-09-22 2004-10-27 Sterix Ltd Compound
DK2206719T3 (en) 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
WO2007081835A2 (en) 2006-01-09 2007-07-19 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082980A1 (es) 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
WO2007103162A2 (en) 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
MX2008014353A (es) * 2006-05-09 2008-11-24 Merck & Co Inc Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos.
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
WO2008064425A1 (en) 2006-11-30 2008-06-05 Solbec Pharmaceuticals Limited Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof
EP2114925B8 (en) 2006-12-22 2013-04-10 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
AU2008222655B2 (en) 2007-03-07 2014-03-27 Infinity Pharmaceuticals, Inc. Cyclopamine lactam analogs and methods of use thereof
US8604004B2 (en) * 2007-10-04 2013-12-10 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
US8642766B2 (en) * 2008-05-05 2014-02-04 Ryan A. Shenvi Synthesis of (+) cortistatin A and related compounds
WO2010024930A2 (en) * 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
WO2010123545A2 (en) 2009-04-22 2010-10-28 President And Fellows Of Harvard College Angiogenesis inhibitors
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
BR112012029437A2 (pt) 2010-05-20 2017-03-07 F Hoffmann - La Roche Ag derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
ES2570748T3 (es) 2010-09-17 2016-05-20 Univ Osaka Nuevo análogo de cortistatina A y uso del mismo
WO2012096934A2 (en) 2011-01-10 2012-07-19 The Scripps Research Institute Inhibitors of retroviral replication
EP2809324B1 (en) 2012-02-02 2018-08-01 Senex Biotechnology, Inc. Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer
WO2013122609A1 (en) 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014134169A1 (en) 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
EP3007686A4 (en) 2013-06-10 2017-03-15 Yeda Research and Development Co., Ltd. Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression
CA2921324C (en) 2013-09-18 2022-11-22 Bcn Peptides S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
PE20161405A1 (es) * 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos

Also Published As

Publication number Publication date
CN106103452B (zh) 2019-05-21
MX2016008436A (es) 2016-12-16
WO2015100420A1 (en) 2015-07-02
PH12016501258A1 (en) 2016-08-15
US20190185484A1 (en) 2019-06-20
AU2019201888A1 (en) 2019-04-11
NI201600089A (es) 2016-08-18
SA516371410B1 (ar) 2019-02-13
RU2016126503A (ru) 2018-01-30
MX361652B (es) 2018-12-13
SG10201808151RA (en) 2018-10-30
SV2016005234A (es) 2018-12-14
DOP2016000158A (es) 2016-10-16
AU2014369834B2 (en) 2018-12-20
BR112016014760A2 (pt) 2017-12-12
ZA201603894B (en) 2018-08-29
US9994582B2 (en) 2018-06-12
RU2016126503A3 (es) 2018-07-17
GT201600135A (es) 2018-11-27
EP3505521A1 (en) 2019-07-03
ES2709480T3 (es) 2019-04-16
EA201891279A1 (ru) 2019-01-31
EP3087080A1 (en) 2016-11-02
CN106103452A (zh) 2016-11-09
SG11201605178WA (en) 2016-07-28
CR20160291A (es) 2017-02-24
PE20161405A1 (es) 2017-01-18
MY180383A (en) 2020-11-28
KR20160101162A (ko) 2016-08-24
IL246390A0 (en) 2016-08-31
JP6494631B2 (ja) 2019-04-03
TN2016000240A1 (en) 2017-10-06
AP2016009324A0 (en) 2016-07-31
AU2014369834A1 (en) 2016-06-23
US20170029435A1 (en) 2017-02-02
US10273241B2 (en) 2019-04-30
JP2019108367A (ja) 2019-07-04
MD20160089A2 (ro) 2016-12-31
US20180319814A1 (en) 2018-11-08
US10508121B2 (en) 2019-12-17
EA030907B1 (ru) 2018-10-31
CA2934819A1 (en) 2015-07-02
CL2016001631A1 (es) 2017-02-24
EA201691167A1 (ru) 2016-11-30
CN110183461A (zh) 2019-08-30
EP3087080B1 (en) 2018-11-28
JP2017509586A (ja) 2017-04-06

Similar Documents

Publication Publication Date Title
ECSP16062174A (es) Análogos de cortistatina y síntesis y usos de los mismos
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CY1119170T1 (el) Ενωση γουανιδινης
HN2012001744A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
BR112013025387A2 (pt) análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
CU24272B1 (es) Derivados de tetrahidropirido-pirimidina como inhibidores de mek
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
UY35185A (es) ?Derivados de 4-(bifenil-3-il)-7H-imidazo[4,5-c]piridazina?.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
UY32574A (es) Antagonistas del receptor cxcr3
UY35012A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MX2018009503A (es) Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, metodos de preparacion y usos.
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
WO2016125190A3 (en) Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
DOP2016000293A (es) Derivados de diheterociclo enlazado a cicloalquilo
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
JO2851B1 (en) 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof.